Company Monitoring Page for JNJ

latest headlines for company on cafepharma

Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?
Motley Fool
Fri, 11/17/23 - 09:59 am
Tags:
JNJ, Intuitive Surgical, Medtech, robotic surgery
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Fierce Biotech
Thu, 11/16/23 - 11:45 am
Tags:
Astellas, Propella Therapeutics, M&A, JNJ, Zytiga, prostate cancer
J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses
Fierce Pharma
Tue, 11/14/23 - 09:56 pm
Tags:
JNJ, Bayer, Xarelto, blood thinners, AHA, peripheral artery disease
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Biopharma Reporter
Thu, 11/9/23 - 09:55 am
Tags:
Janssen, JNJ, rheumatoid arthritis, nipocalimab, clinical trials
J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina
Fierce Pharma
Wed, 11/8/23 - 09:57 pm
Tags:
JNJ, Janssen, Fujifilm Diosynth Biotechnologies, CDMOs, North Carolina
J&J targets 2024 for Ottava FDA filing
Medtech Dive
Tue, 11/7/23 - 11:05 pm
Tags:
JNJ, Medtech, Ottava, robotic surgery
HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations
BioSpace
Tue, 11/7/23 - 09:48 am
Tags:
JNJ, Stelara, HHS, Inflation Reduction Act, Medicare, drug pricing
Study of Johnson & Johnson device shows promising results for AFib
Clinical Trials Arena
Fri, 11/3/23 - 10:54 am
Tags:
JNJ, Medtech, QDOT MICRO, atrial fibrillation
Amgen scores FDA approval for Stelara biosimilar
Pharmaceutical Technology
Wed, 11/1/23 - 10:16 pm
Tags:
Amgen, Stelara, biosimilars, JNJ, FDA, Wezlana
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
Reuters
Tue, 10/31/23 - 10:18 am
Tags:
GSK, JNJ, hepatitis B, JNJ-3989, Janssen
Cidara’s J&J-partnered immunotherapy could target flu and cancer
Pharma Voice
Thu, 10/26/23 - 10:35 am
Tags:
Cidara, JNJ, immunotherapy, drug-Fc conjugates, cancer, Flu
Janssen reports data from Phase III trial of lung cancer drug
Clinical Trials Arena
Tue, 10/24/23 - 10:21 am
Tags:
JNJ, Janssen, Rybrevant, clinical trials, non-small cell lung cancer
J&J bites back against dengue, linking antiviral to protection from infection in challenge trial
Fierce Biotech
Fri, 10/20/23 - 10:15 am
Tags:
JNJ, dengue, JNJ-1802, antiviral
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
Fri, 10/20/23 - 10:05 am
Tags:
ESMO, non-small cell lung cancer, Roche, Alecensa, AstraZeneca, Tagrisso, JNJ, Rybrevant
Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?
Medical Marketing and Media
Thu, 10/19/23 - 11:29 am
Tags:
JNJ, Rybrevant, AstraZeneca, Tagrisso, EGFR-mutated NSCLC
After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti
Fierce Pharma
Wed, 10/18/23 - 07:44 pm
Tags:
JNJ, Legend Biotech, Multiple Myeloma, CAR-T, Carvykti, cell therapy
Why Johnson & Johnson Stock Flopped Today
Motley Fool
Wed, 10/18/23 - 07:39 pm
Tags:
JNJ, earnings, analysts
J&J Signals Exit from Less Profitable Orthopedic Markets
Medical Devices and Diagnostics Industry
Wed, 10/18/23 - 10:14 am
Tags:
JNJ, Medtech, Orthopedics
J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance
BioSpace
Tue, 10/17/23 - 09:39 pm
Tags:
JNJ, earnings
Janssen’s Tremfya maintains three years of remission in Phase II Crohn’s disease trial
Clinical Trials Arena
Tue, 10/17/23 - 11:45 am
Tags:
JNJ, Janssen, clinical trials, Crohn's Disease, Tremfya

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.